07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

Medical Research Council pharmaceuticals news

The U.K.'s three-year, £180 million ($285.8 million) Biomedical Catalyst fund awarded £9.9 million ($15.6 million) across 14 U.K. universities and 18 small and medium sized enterprises (SMEs) for early stage life science research. Each university...
23:46 , Aug 1, 2012 |  BC Extra  |  Politics & Policy

U.K. biomedical fund announces first awards

The U.K.'s three-year, L180 million ($285.8 million) Biomedical Catalyst fund awarded L9.9 million ($15.6 million) across 14 U.K. universities and 18 small and medium sized enterprises (SMEs) for early stage life science research. Each university...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Company News

Absynth Biologics, MorphoSys deal

The companies will discover and develop antibodies against Absynth's targets associated with Staphylococcus aureus infections, including methicillin-resistant S. aureus (MRSA). MorphoSys will generate antibodies using its HuCAL PLATINUM antibody library, and Absynth will test the...
07:00 , Sep 6, 2010 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.86 (11%) to $9.03 last week after FDA accepted for filing and granted Priority Review to an NDA for Iluvien to treat diabetic macular edema (DME). The company...
00:06 , Sep 3, 2010 |  BC Extra  |  Company News

MorphoSys, Absynth in infectious deal

MorphoSys AG (Xetra:MOR) partnered with Absynth Biologics Ltd. (Sheffield, U.K.) to discover and develop antibodies against Absynth's targets associated with Staphylococcus aureus infections including methicillin-resistant S. aureus (MRSA). MorphoSys will generate antibodies using...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

Biofusion plc, University of Sheffield deal

The university spun out Absynth Biologics Ltd. (Sheffield, U.K.), which will use the university’s antibody-recognition technology to develop vaccines and antibodies against S. aureus, including methicillin-resistant S. aureus (MRSA). BFN, which invested £325,000 ($637,000)...